Skip to content

ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS

  • Dorrit Walsh
Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.
Read more

How Rising Anti-LGBTQ Sentiment Harms Public Health

  • Dorrit Walsh

By Kendall Martinez-Wright, Elizabeth Lovinger, and De’Ashia Lee Many people recognize advances the LGBTQ+ community has made in the United States and other countries, including the freedom to marry their partners, sexual orientation and gender identity protections, and the fact…

Read more

Are We There Yet? TB Preventive Treatment Beyond TB/HIV Integration

  • Dorrit Walsh

By Lynette Mabote-Eyde and Mike Frick Too often, major scientific advancements against tuberculosis (TB) get lost on the long and winding road of policy translation into practice. TB preventive treatment (TPT) has faced decades of dislocation between progressive global World…

Read more
October 2023 TAGline cover: Lost in Translation. Features graphic of "TAG Translate" and shows 4 sets of terms: Shorter Treatments = Error: Insufficient Funding; Community Engagement = Error: political hostility; effective prevention = error inadequate awareness; broad screening = error: outdated guidelines

TAGline October 2023

  • Dorrit Walsh
We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.
Read more

TAG Reacts to J&J Commitment to Not Enforce Patents on Bedaquiline

  • Dorrit Walsh
TAG is thrilled by this weekend’s announcement that following years of activist pressure, Johnson & Johnson (J&J) has finally publicly committed to not enforcing its spurious secondary patents on bedaquiline in the treatment of drug-resistant tuberculosis (DR-TB) in 134 low- and middle-income countries.
Read more

TAG Response to TB Preventive Therapy Price Cut Announcement from USAID and PEPFAR

  • Dorrit Walsh
TAG welcomes the joint announcement from USAID and PEPFAR at the CDC’s “Prevent TB to End TB” event on the sidelines of the United Nations High-Level Meeting on TB that they have secured a 30% price reduction on the tuberculosis preventive treatment (TPT) regimen called 3HP, taking the price from $14.25 to $9.99 for a three-month patient course.
Read more
Back To Top